Structure Therapeutics reports new data on oral amylin and GLP-1 obesity drugs
The company disclosed Phase 1/2a data on ACCG-2671 and 72-week extension results for aleniglipron, an oral GLP-1 candidate now in Phase 3.
SEC filing
Latest
2 stories
Tuesday, September 8
Thursday, August 6
Structure Therapeutics doses first patients in Phase 3 obesity program for aleniglipron
The company started its ACCOMPLISH-1 and -2 trials as it reported second-quarter 2026 results and named a new chief commercial officer.
SEC filing